Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 03, 2025 08:00 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum

Company advances JOTROL™ into Phase 2a Parkinson’s trial, launches Nugevia™ consumer brand, and strengthens financial position Jupiter, Florida, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Jupiter...
November 05, 2025 08:30 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease

Jupiter, Florida, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based therapeutic...
August 11, 2025 08:00 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience

MND combines proprietary resveratrol-based platform and NovaSOL® Curcumin to enhance cognitive performance and support neuroprotective health Jupiter, Florida, Aug. 11, 2025 (GLOBE NEWSWIRE) --...
July 10, 2025 16:05 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Nasdaq compliance follows positive upward trend in Company’s Stock Price Jupiter, Florida, July 10, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the...
June 30, 2025 15:15 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

PWR delivers science-driven cellular energy and recovery support as part of Jupiter’s expanding longevity supplement portfolio Jupiter, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- Jupiter...
June 27, 2025 08:00 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science

GLO targets the growing ”beauty-from-within” market with scientifically proven cellular defense and skin vitality benefits Jupiter, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- Jupiter...
June 09, 2025 07:00 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science

First consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's evolution Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter...
April 08, 2025 08:00 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter

Strategic expansion into longevity market creates near-term commercial opportunity alongside continued clinical advancement of JOTROL™ JOTROL™ development programs remain tariff-exempt; consumer...
March 04, 2025 08:00 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products

First three consumer products expected to launch in Q3 2025, providing near-term revenue growth Jupiter, Florida, March 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS)...
February 04, 2025 09:25 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones

Jupiter, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented...